肠道微生态与炎症性肠病

何丽娟; 张军东; 安毛毛; 姜远英

doi:10.3969/j.issn.1006-0111.2015.05.001

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

1.
第二军医大学药学院新药研究中心, 上海 200433
2.
同济大学附属第十人民医院, 上海 200072
3.
同济大学医学院, 上海 200092

Gut microbiota and inflammatory bowel disease

1.
New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China
3.
School of Medicine, Tongji University, Shanghai 200092, China

摘要: 炎症性肠病(inflammatory bowel disease,IBD)是一组病因未明、发病机制亦不明确的慢性肠道炎症性疾病,主要包括克罗恩病(Crohn's disease,CD)和溃疡性结肠炎(ulcerative colitis,UC)。近几十年的研究结果认为,其发病是环境、易感基因和肠道微生态3个要素相互作用的结果,且这些要素使IBD成为一种适合研究宿主与肠道微生物相互作用的高优先平台。最近,肠道菌群的图谱分析将IBD的发病机制与菌群各组成部分特征的改变相联系,进一步支持"肠道微生物和宿主相互作用的改变能形成IBD"这一观点。该文回顾性分析有关IBD患者体内微生物的研究文献,综述肠道微生态失衡对IBD的多方面影响,以动物模型和临床验证资料阐述不同的治疗方法改善肠道微生态变化的最新进展。
- 炎症性肠病 /
- 肠道微生态 /
- 相互作用
Abstract: Inflammatory bowel disease is a chronic inflammation of the intestinal tract, which comprises two primary forms of Crohn's disease(CD) and ulcerative colitis(UC). Decades of studies have revealed that environmental factors, susceptibility genes, and gut microbiota are considered as the major determinants for the induction of IBD. The combination of factors has made IBD as an appropriate and a high-priority platform for studying host-microbiome interactions. More recently, profiling studies of the intestinal microbe have associated pathogenesis of IBD with characteristic alterations in the composition of the intestinal microbiota,reinforcing the viewpoint that IBD results from the altered interplays between the host and intestinal microbe. the studies of the gut flora in IBD were reviewed andthe multiple effects of intestinal microbiota-dysfunction on the IBD were described.The progress of intestinal microbiota alterations with different therapeutic methods in animal models and clinic trials were provided.
- inflammatory bowel disease /
- intestinal microbe /
- interaction

[1]	Molodecky NA,Soon IS,Rabi DM,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012, 142(1):46-54.
[2]	Dave M,Higgins PD,Middha S,et al. The human gut microbiome: current knowledge,challenges,and future directions[J].Transl Res,2012,160(4):246-257.
[3]	Huttenhower C,Kostic AD,Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome[J]. Immunity,2014,40(6):843-854.
[4]	Morgan XC,Segata N,Huttenhower C. Biodiversity and functional genomics in the human microbiome[J]. Trends Genet,2013,29(1):51-58.
[5]	Scaldaferri F,Gerardi V,Lopetuso LR,et al. Gut microbial flora,prebiotics,and probiotics in IBD: their current usage and utility[J]. Biomed Res Int,2013,2013:435268.
[6]	Hooper LV,Littman DR,Macpherson AJ. Interactions between the microbiota and the immune system[J].Science,2012,336(6086):1268-1273.
[7]	Boudeau J,Glasser AL,Masseret E,et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease[J].Infect Immun,1999,67(9):4499-4509.
[8]	Rolhion N,Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Inflamm Bowel Dis,2007,13(10):1277-1283.
[9]	Allen-Vercoe E,Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC?[J].Immunol Lett,2014,162(2PA):54-61.
[10]	Allen-Vercoe E,Strauss J,Chadee K. Fusobacterium nucleatum: an emerging gut pathogen?[J].Gut Microb,2011,2(5):294-298.
[11]	Ohkusa T,Okayasu I,Ogihara T,et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J]. Gut,2003,52(1):79-83.
[12]	Strauss J,Kaplan GG,Beck PL,et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host[J]. Inflamm Bowel Dis,2011,17(9):1971-1978.
[13]	Kostic AD,Chun E,Robertson L,et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microb,2013,14(2):207-215.
[14]	Kitajima S,Morimoto M,Sagara E,et al. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice[J]. Exp Anim,2001,50(5):387-395.
[15]	Kamada N,Chen G,Núez G. A complex microworld in the gut: harnessing pathogen-commensal relations[J]. Nat Med,2012,18(8):1190-1191.
[16]	Llopis M,Antolin M,Carol M,et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa[J]. Inflamm Bowel Dis,2009,15(2):275-283.
[17]	Varela E,Manichanh C,Gallart M,et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis[J]. Aliment Pharmacol Ther,2013,38(2):151-161.
[18]	Cadwell K,Patel KK,Maloney NS,et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine[J]. Cell,2010,141(7):1135-1145.
[19]	Trojanowska D,Zwolinska-Wcislo M,Tokarczyk M,et al. The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains[J]. Med Sci Monit,2010,16(10):CR451-457.
[20]	Iliev ID,Funari VA,Taylor KD,et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis[J]. Science,2012,336(6086):1314-1317.
[21]	Morgan XC,Tickle TL,Sokol H,et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J]. Genome Biol,2012,13(9):R79.
[22]	Atarashi K,Tanoue T,Oshima K,et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota[J]. Nature,2013,500(7461):232-236.
[23]	Duncan SH,Hold GL,Barcenilla A,et al.Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces[J]. Int J Syst Evol Microbiol, 2002,52(Pt 5):1615-1620.
[24]	Khan KJ,Ullman TA,Ford A,et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and Meta-analysis[J]. Am J Gastroenterol,2011,106(4):661-673.
[25]	Lemon KP,Armitage GC,Relman DA,et al. Microbiota-targeted therapies: an ecological perspective[J]. Sci Transl Med,2012,4(137):137rv5.
[26]	Gevers D,Kugathasan S,Denson LA,et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microb,2014,15(3):382-392.
[27]	Wlodarska M,Willing B,Keeney KM,et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium induced colitis[J]. Infect Immun,2011,79(4):1536-1545.
[28]	Damman CJ,Miller SI,Surawicz CM,et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?[J].Am J Gastroenterol,2012,107(10):1452-1459.
[29]	Shahinas D,Silverman M,Sittler T,et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing[J]. MBio,2012,3(5):e00338-12.
[30]	Anderson JL,Edney RJ,Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Aliment Pharmacol Ther,2012,36(6):503-516.
[31]	Morgan XC,Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome[J]. Gastroenterology,2014,146(6):1437-1448.

[1]	邵尉, 袁妮, 刘叶, 于飞, 柳莹, 王峰. 丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析 . 药学实践与服务, 2025, 43(8): 1-5. doi: 10.12206/j.issn.2097-2024.202408046
[2]	何琳, 成彦琼, 叶侃倜, 赵娟娟, 陆蕙兰, 杨骏, 陈方剑. 血通胶囊降血脂以及肝脏保护作用研究 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202502015
[3]	王新霞, 刘祉君, 吕磊, 张爽, 高守红. 鬼针草降压作用研究及展望 . 药学实践与服务, 2025, 43(9): 427-430. doi: 10.12206/j.issn.2097-2024.202408021
[4]	关梦瑶, 夏天爽, 何旭辉, 史策, 蒋益萍, 辛海量. 黑蒜多糖抗便秘作用研究 . 药学实践与服务, 2025, 43(4): 190-194. doi: 10.12206/j.issn.2097-2024.202403059
[5]	周文艳, 胡珊珊, 张万年, 庄春林. Keap1-Nrf2通路在炎症疾病中的研究进展 . 药学实践与服务, 2025, 43(3): 97-108, 116. doi: 10.12206/j.issn.2097-2024.202405013
[6]	晁亮, 王辉, 沈淑琦, 游飘雪, 冀凯宏, 洪战英. 基于UHPLC-Q/TOF-MS代谢组学策略的葛根-知母药对防治阿尔茨海默病的药效与作用机制研究 . 药学实践与服务, 2025, 43(1): 30-40. doi: 10.12206/j.issn.2097-2024.202409035
[7]	于翔, 贾培培, 李欣颖, 杨君君, 郭高峰, 陆连芳. M2型巨噬细胞外泌体喷剂对压力性损伤的疗效及作用机制 . 药学实践与服务, 2025, 43(9): 436-442. doi: 10.12206/j.issn.2097-2024.202503066
[8]	彭莹, 刘欣, 聂依文, 王歆荷, 年华, 朱建勇. 三种狼毒乙醇提取物对咪喹莫特诱导的银屑病小鼠防治作用研究 . 药学实践与服务, 2025, 43(): 1-6. doi: 10.12206/j.issn.2097-2024.202406029
[9]	黄欣, 杨茹洁, 秦峰, 张士莲, 吴莘, 尹小燕. 硫酸镁钠钾口服液在内镜肠道清洁准备中的效果 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202311049
[10]	柯刚, 董清科, 肖世容, 龚茜, 李荣, 汪代杰. 基于网络药理学探讨参苓白术散治疗肿瘤恶病质的作用机制 . 药学实践与服务, 2025, 43(5): 242-250. doi: 10.12206/j.issn.2097-2024.202208115
[11]	肖农, 陆诗依, 唐文雅, 居敏俐, 徐刚锋, 杨明华. 中成药微生物计数法前处理的影响因素和优化方法 . 药学实践与服务, 2025, 43(8): 373-376, 409. doi: 10.12206/j.issn.2097-2024.202403014
[12]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2025, 43(3): 143-150. doi: 10.12206/j.issn.2097-2024.202312027
[13]	曹金发, 钟玲, 何苗, 田泾. 1例炎症性肠病合并心房颤动患者的用药分析与监护 . 药学实践与服务, 2025, 43(10): 525-528. doi: 10.12206/j.issn.2097-2024.202403004
[14]	李清, 郭宜银, 陈颖, 瞿发林, 董文燊, 戈煜. 夜宁胶囊对小鼠镇静催眠作用及其机制的研究 . 药学实践与服务, 2024, 42(8): 346-349. doi: 10.12206/j.issn.2097-2024.202211047
[15]	张林晨, 张小琴, 张俊平. 山楂酸药理作用的研究进展 . 药学实践与服务, 2024, 42(5): 185-189. doi: 10.12206/j.issn.2097-2024.202307052
[16]	钱淑雨, 李铁军. 耐碳青霉烯类肠杆菌耐药机制的研究进展 . 药学实践与服务, 2024, 42(10): 419-425. doi: 10.12206/j.issn.2097-2024.202405005
[17]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[18]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[19]	岳春华, 贲永光, 王海桥. 基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
[20]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023

点击查看大图

计量

文章访问数: 4838
HTML全文浏览量: 428
PDF下载量: 599
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

Gut microbiota and inflammatory bowel disease

计量

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

1. 第二军医大学药学院新药研究中心, 上海 200433

2. 同济大学附属第十人民医院, 上海 200072

3. 同济大学医学院, 上海 200092

English Abstract

Gut microbiota and inflammatory bowel disease

1. New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China

3. School of Medicine, Tongji University, Shanghai 200092, China

全文HTML

目录

留言板

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

Gut microbiota and inflammatory bowel disease

计量

出版历程

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001

1. 第二军医大学药学院新药研究中心, 上海 200433 2. 同济大学附属第十人民医院, 上海 200072 3. 同济大学医学院, 上海 200092

English Abstract

Gut microbiota and inflammatory bowel disease

1. New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China 2. Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China 3. School of Medicine, Tongji University, Shanghai 200092, China

全文HTML

目录

1. 第二军医大学药学院新药研究中心, 上海 200433

2. 同济大学附属第十人民医院, 上海 200072

3. 同济大学医学院, 上海 200092

1. New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China

3. School of Medicine, Tongji University, Shanghai 200092, China